Observational Studies in COPD: Summary of Guidance for Authors

References

• Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61(11):935–939.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963.
   PubMed Web of Science ®Google Scholar
• Gedebjerg A, Szépligeti SK, Wackerhausen L-MH, Horváth-Puhó E, Dahl R, Georg Hansen J, Sørensen HT, Nørgaard M, Lange P, Thomsen RW. Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study. Lancet Respir Med. 2018;6(3):204–212. doi:10.1016/S2213-2600(18)30002-X.
   PubMed Web of Science ®Google Scholar
• Gershon AS, Campitelli MA, Croxford R, Stanbrook MB, To T, Upshur R, Stephenson AL, Stukel TA. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014;312(11):1114–1121.
   PubMed Web of Science ®Google Scholar
• Di Martino M, Agabiti N, Cascini S, Kirchmayer U, Bauleo L, Fusco D, Belleudi V, Pinnarelli L, Voci C, Patorno E, et al. The effect on total mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: a real practice analysis in Italy. COPD. 2016;13(3):293–302. doi:10.3109/15412555.2015.1044861.
   PubMedGoogle Scholar
• Suissa S, Dell'Aniello S, Ernst P. Long-acting bronchodilator initiation in COPD and the risk of adverse cardiopulmonary events: a population-based comparative safety study. CHEST. 2017;151(1):60–67.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell'Aniello S, Ernst P. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J. 2017;49(5)
   Web of Science ®Google Scholar
• Suissa S, Dell'Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018;6(11):855–862. doi:10.1016/S2213-2600(18)30368-0.
   PubMed Web of Science ®Google Scholar
• Guyatt G, Cairns J, Churchill D, Cook D, Haynes B, Hirsh J, Irvine J, Levine M, Levine M, Nishikawa J, et al. Evidence-based medicine: A new approach to teaching the practice of medicine. JAMA. 1992;268(17):2420–2425. doi:10.1001/jama.1992.03490170092032.
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–1892.
   PubMed Web of Science ®Google Scholar
• Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550–560. doi:10.1097/00001648-200009000-00011.
   PubMed Web of Science ®Google Scholar
• Sana A, Somda SMA, Meda N, Bouland C. Chronic obstructive pulmonary disease associated with biomass fuel use in women: a systematic review and meta-analysis. BMJ Open Respir Res. 2018;5(1)
   PubMed Web of Science ®Google Scholar
• Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in chronic obstructive pulmonary disease. Eur Respir J. 2006;29(2)
   PubMed Web of Science ®Google Scholar
• Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162–166.
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, Ställberg B, Stratelis G, Goike H, Jörgensen L, Johansson G. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346
   PubMedGoogle Scholar
• Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036.
   PubMed Web of Science ®Google Scholar
• Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, Ost DE, Punjabi NM, Schatz M, Smyth AR, et al. Control of confounding and reporting of results in causal inference studies: guidance for authors from editors of respiratory, sleep, and critical care journals. Ann Am Thor Soc. 2018
   Web of Science ®Google Scholar
• Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241–249.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492–499.
   PubMed Web of Science ®Google Scholar
• Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008;168(3):329–335.
   PubMed Web of Science ®Google Scholar
• Kiri VA, Pride NB, Soriano JB, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med. 2005;172(4):460–464.
   PubMed Web of Science ®Google Scholar
• Suissa S. Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias. Am J Respir Crit Care Med. 2006;173(4):464–465. doi:10.1164/ajrccm.173.4.464.
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P. Observational studies of inhaled corticosteroid effectiveness in COPD: lessons learned. CHEST. 2018;154(2):257–265.
   PubMed Web of Science ®Google Scholar
• Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med. 2009;9(1):32.
   PubMedGoogle Scholar
• Horita N, Miyazawa N, Kojima R, Inoue M, Ishigatsubo Y, Ueda A, Kaneko T. Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies. Respir Res. 2014;15(1):80.
   PubMedGoogle Scholar
• Suissa S. Co-morbidity in COPD: the effects of cardiovascular drug therapies. Respiration. 2010;80(1):3–7.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield MT, Han MK, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23)
   PubMed Web of Science ®Google Scholar
• Suissa S. Simvastatin in moderate-to-severe COPD. N Engl J Med. 2014;371(10):969–970.
   PubMedGoogle Scholar